Theranostics 2019; 9(17):5085-5104. doi:10.7150/thno.34415 This issue Cite

Review

Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology

Benjamin B. Kasten1, Neha Udayakumar2, Jianmei W. Leavenworth1, Anna M. Wu3, Suzanne E. Lapi4, Jonathan E. McConathy4, Anna G. Sorace4, Asim K. Bag5, James M. Markert1, Jason M. Warram6✉

1. Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, United States.
2. School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
3. Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States.
4. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
5. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, United States.
6. Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, United States.

Citation:
Kasten BB, Udayakumar N, Leavenworth JW, Wu AM, Lapi SE, McConathy JE, Sorace AG, Bag AK, Markert JM, Warram JM. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics 2019; 9(17):5085-5104. doi:10.7150/thno.34415. https://www.thno.org/v09p5085.htm
Other styles

File import instruction

Abstract

Graphic abstract

Imaging plays a central role in evaluating responses to therapy in neuro-oncology patients. The advancing clinical use of immunotherapies has demonstrated that treatment-related inflammatory responses mimic tumor growth via conventional imaging, thus spurring the development of new imaging approaches to adequately distinguish between pseudoprogression and progressive disease. To this end, an increasing number of advanced imaging techniques are being evaluated in preclinical and clinical studies. These novel molecular imaging approaches will serve to complement conventional response assessments during immunotherapy. The goal of these techniques is to provide definitive metrics of tumor response at earlier time points to inform treatment decisions, which has the potential to improve patient outcomes. This review summarizes the available immunotherapy regimens, clinical response criteria, current state-of-the-art imaging approaches, and groundbreaking strategies for future implementation to evaluate the anti-tumor and immune responses to immunotherapy in neuro-oncology applications.

Keywords: neuro-oncology, immunotherapy, imaging, response, MRI, PET


Citation styles

APA
Kasten, B.B., Udayakumar, N., Leavenworth, J.W., Wu, A.M., Lapi, S.E., McConathy, J.E., Sorace, A.G., Bag, A.K., Markert, J.M., Warram, J.M. (2019). Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics, 9(17), 5085-5104. https://doi.org/10.7150/thno.34415.

ACS
Kasten, B.B.; Udayakumar, N.; Leavenworth, J.W.; Wu, A.M.; Lapi, S.E.; McConathy, J.E.; Sorace, A.G.; Bag, A.K.; Markert, J.M.; Warram, J.M. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics 2019, 9 (17), 5085-5104. DOI: 10.7150/thno.34415.

NLM
Kasten BB, Udayakumar N, Leavenworth JW, Wu AM, Lapi SE, McConathy JE, Sorace AG, Bag AK, Markert JM, Warram JM. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics 2019; 9(17):5085-5104. doi:10.7150/thno.34415. https://www.thno.org/v09p5085.htm

CSE
Kasten BB, Udayakumar N, Leavenworth JW, Wu AM, Lapi SE, McConathy JE, Sorace AG, Bag AK, Markert JM, Warram JM. 2019. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics. 9(17):5085-5104.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image